增强型体外反搏联合瑞舒伐他汀对行PCI术治疗的急性心肌梗死患者预后的影响

doi:10.3969/j.issn.1671-7171.2021.06.021

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1143 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the effect of enhanced external counterpulsation combined with rosuvastatin on the prognosis of patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI).【Methods】From April 2018 to June 2020, 116 AMI patients who underwent PCI in our hospital were prospectively selected and randomly divided into observation group and control group, 58 cases in each group. The control group was treated with rosuvastatin after PCI, and the observation group was treated with enhanced external counterpulsation on the basis of the control group for 1 month. The curative effects of the two groups were compared with the indexes of cardiac function [left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV)], hemorheological indexes (whole blood high shear viscosity, whole blood low shear viscosity, erythrocyte sedimentation rate, fibrinogen), serum vascular endothelial function indexes [nitric oxide, Endothelin-1 (ET-1) and von Willebrand factor (vWF)] before and 1 month after operation were measured. The incidence of major adverse cardiovascular events (MACE) 1 month after operation was recorded.【Results】The total effective rate of observation group was 91.38% (53/58), which was higher than that of the control group [75.86% (44/58], and the difference was statistically significant(χ²=5.098,P=0.024＜0.05). The LVEF level of the two groups was higher than that of the control group one month after operation, and the LVEDV and LVESV levels in the observation group were lower than that of the control group (P<0.05); The whole blood viscosity, whole blood low shear viscosity, erythrocyte sedimentation rate and fibrinogen were lower in the two groups than that in the control group (P<0.05); The serum NO level of the two groups was higher than that of the control group, ET-1 and vWF were lower than that of the control group (P<0.05); The incidence of mace in the observation group was 6.90% (4/58), which was lower than that of the control group (22.41% (13/58), and the difference was statistically significant(χ²=5.583,P=0.018＜0.05).【Conclusion】Enhanced external counterpulsation combined with rosuvastatin has significant effect in patients after AMI PCI, which can improve the cardiac function and reduce the risk of mace.

Key words： Myocardial Infarction Acute Disease Hydroxymethylglutaryl-CoA Reductase Inhibitors/AD Counterpulsation Prognosis

Received: 22 October 2020

PACS:

R542.22

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Wen-he
	SUN Ya-lan
	ZHANG Shou-ben

Cite this article:

HAN Wen-he,SUN Ya-lan,ZHANG Shou-ben. Effect of Enhanced External Counterpulsation Combined with Rosuvastatin on Prognosis of Patients with Acute Myocardial Infarction Undergoing PCI[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(6): 879-882.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2021.06.021 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2021/V38/I6/879

[1] ZIMOCH WJ,KUBLER P,KOSOWSKI M,et al.Patients with acute myocardial infarction and severe target lesion calcifications undergoing percutaneous coronary intervention have poor long term prognosis[J].Kardiol Pol,2017,75(9):859-867.
[2] 常国栋,陈英伟.替格瑞洛在氯吡格雷抵抗急性心肌梗死患者PCI术后抗血小板治疗中的应用效果[J].中国循证心血管医学杂志,2018,10(4):466-468.
[3] LüSCHER TF.The search for optimal dual antiplatelet therapy after PCI:fine-tuning of initiation and duration[J].Eur Heart J,2016,37(4):319-321.
[4] 卓碧,韦庆新,韦盛锴,等.不同剂量瑞舒伐他汀对急性心肌梗死患者经皮冠状动脉介入治疗术后血清炎症因子及心功能相关指标的影响[J].山西医药杂志,2017,46(13):1551-1553.
[5] 黄勇,李蔚华,尹虹,等.体外反搏联合麝香保心丸对急性心肌梗死患者PCI术后GDF-15、IL-6的影响[J].现代中西医结合杂志,2018,27(14):1560-1562.
[6] WANG X F,YE M,YAN D,et al.Non-invasive ventilation improves hemorheology status in hypoxemic patients with acute myocardial infarction after PCI[J].J Geriatr Cardiol,2017,14(4):274-279.
[7] 吴平平,张红心,王秀梅,等.负荷剂量辛伐他汀对急性心肌梗死患者PCI围术期相关指标的影响[J].中国药房,2017,28(6):776-779.
[8] THIELE H,AKIN I,SANDRI M,et al.PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock[J].N Engl J Med,2017,377(25):2419-2432.
[9] 邓先科,梁丕,和至峰.瑞舒伐他汀对急性心肌梗死患者经皮冠状动脉介入治疗后炎性因子及血液流变学相关指标的影响[J].岭南心血管病杂志,2019,25(4):393-395.
[10] 黄渝杰,左中.内皮切应力在增强型体外反搏治疗中调节内皮功能的分子机制研究进展[J].心血管病学进展,2019,40(3):467-470.
[11] TONG J,YU Q,LI C,et al.Successful revascularization of noninfarct related artery with chronic total occlusion among acute myocardial infarction patients:A systematic review and meta-analysis[J].Medicine,2018,97(3):e9655.
[12] 李辉,许艳春.瑞舒伐他汀对PCI术后患者血管内皮功能、炎性因子的影响[J].海南医学院学报,2017,23(2):162-164.
[13] 王东江,黄鲁,王莹,等.培哚普利对急性心肌梗死患者血管内皮功能及EPCs水平的干预作用[J].解放军预防医学杂志,2019,37(6):30-31.